Biological E's ‘Corbevax’ gets DCGI approval for two clinical trials | Latest News India - Hindustan Times
close_game
close_game

Biological E's ‘Corbevax’ gets DCGI approval for two clinical trials

By | Written by Kunal Gaurav, Hindustan Times, New Delhi
Sep 03, 2021 03:08 PM IST

Biological E received approval for Phase 3 comparator safety and immunogenicity trial in adults after a review of Phase 1 and 2 clinical trials data by a subject expert committee.

The Drugs Controller General of India (DCGI) has given approval to Biological E for two clinical trials of its Covid-19 vaccine candidate Corbevax, the ministry of science and technology announced Friday. The Hyderabad-based pharmaceutical company received approval for Phase 3 comparator safety and immunogenicity trial in adults after a review of Phase 1 and 2 clinical trials data by a subject expert committee.

Union health minister Mansukh Mandaviya meets Mahima Datla, MD of Biological E. Limited, in New Delhi.(ANI / File Photo)
Union health minister Mansukh Mandaviya meets Mahima Datla, MD of Biological E. Limited, in New Delhi.(ANI / File Photo)

It also received approval for the Phase 2/3 study to evaluate the “safety, reactogenicity, tolerability and immunogenicity” of Corbevax in children and adolescents.

Hindustan Times - your fastest source for breaking news! Read now.

Dr Renu Swarup, secretary, the department of biotechnology (DBT), said that the department is committed to the development of safe and efficacious Covid-19 vaccines. Swarup, who is also chairperson of Biotechnology Industry Research Assistance Council (BIRAC), said in a statement that they look forward to the clinical development of Corbevax for paediatric and adults.

Mahima Datla, Managing Director, Biological E. Limited, expressed delight over the “significant approvals” from the DCGI. Datla said in a statement that these approvals encourage the company to move forward and successfully produce the Covid-19 vaccine to meet the country’s needs.

“We are grateful to BIRAC for their support and we are enthused that these approvals would help support our subsequent filings with WHO as well. We appreciate and acknowledge the contribution of all our collaborators for their continued support in this endeavour,’’ she added.

Also Read | Biological E’s Corbevax may be launched in October: Niti Aayog’s VK Paul

The ministry said that the DBT and BIRAC have supported Corbevax, which is an RBD protein subunit vaccine, from the preclinical stage to Phase 3 clinical studies. The Biological E’s vaccine candidate has also received financial support assistance under Covid-19 Research Consortia through National Biopharma Mission, BIRAC.

On Thursday, Niti Aayog member (health) Dr VK Paul said that results of Phase 3 trials of Corbevax were awaited and the company had committed to supply a significant quantity of the vaccine by the end of the year.

“Stockpile is being produced. We should wait for the results. We hope it’ll be in the next month or two. They’ve made a broad commitment that they’ll supply a significant amount by year-end,” news agency ANI quoted Dr Paul as saying.

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Arvind Kejriwal News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, March 28, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On